Related Experiment Video

Updated: Jan 1, 2026

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
09:40

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

3.1K

lncRNA SNHG5 Modulates Endometrial Cancer Progression via the miR-25-3p/BTG2 Axis

Shi Li1,2, Yanan Shan1, Xiaoya Li1

  • 1Research Centre, The Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, China.

Journal of Oncology
|December 31, 2019
PubMed

Insights

The SNHG5/miR-25-3p/BTG2 axis impacts endometrial carcinoma (EC) progression. SNHG5 inhibits EC cell growth by targeting miR-25-3p, which in turn affects BTG2, offering potential for EC diagnosis and therapy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Endometrial carcinoma (EC) is a prevalent female genital malignancy.
  • The molecular mechanisms driving EC initiation and progression are not fully elucidated.

Purpose of the Study:

  • To investigate the role of the noncoding RNA SNHG5 in endometrial carcinoma.
  • To identify the molecular targets and pathways regulated by SNHG5 in EC.

Main Methods:

  • In vitro experiments assessing cell proliferation, migration, and invasion.
  • Analysis of gene and microRNA expression in EC cell lines and tissues.
  • Luciferase reporter assays to confirm direct binding of miR-25-3p to BTG2 mRNA.

Main Results:

  • SNHG5 suppressed proliferation, migration, and invasion of EC cells by inhibiting miR-25-3p.
  • Overexpression of miR-25-3p promoted EC cell growth and invasion.
  • miR-25-3p directly targeted and repressed BTG2 expression.
  • EC tissues exhibited elevated miR-25-3p and reduced SNHG5 and BTG2 levels.
  • SNHG5 expression correlated negatively with miR-25-3p and positively with BTG2.

Conclusions:

  • The SNHG5/miR-25-3p/BTG2 signaling axis is crucial for endometrial carcinoma progression.
  • This axis represents a potential therapeutic target and diagnostic biomarker for EC.

More Related Videos

Genome-wide Screen for miRNA Targets Using the MISSION Target ID Library08:40

Genome-wide Screen for miRNA Targets Using the MISSION Target ID Library

Published on: April 6, 2012

17.9K

Related Concept Videos

lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
9.7K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

3.4K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.7K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
23.8K
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.5K